Bellen Chemistry Joins the Pharmaceutical Supply Chain Initiative (PSCI)

Recently, Bellen's wholly-owned subsidiary, Bellen Chemistry Co., Ltd, Yantai, successfully passed the audit by the PSCI Secretariat and officially became a member of the Pharmaceutical Supply Chain Initiative (PSCI). This achievement reflects the company's ongoing commitment to its sustainable development management system and opens up new opportunities for the company to participate in global pharmaceutical supply chain collaboration. Bellen focuses on providing CRO/CDMO services for the chemical synthesis of small-molecule innovative drugs. As the global pharmaceutical industry continuously raises requirements for supply chain transparency and social responsibility, the company has integrated ESG management into the foundational framework of its corporate development, steadily advancing standardized practices in production operations, environmental protection, and employee rights protection.

PSCI advocates for suppliers to establish systematic management mechanisms in areas such as safety, environment, business ethics, and labor rights. Becoming a PSCI membership means that Bellen will build upon its existing efforts, utilize the industry guidelines and collaborative networks provided by PSCI to continuously improve its management systems, and actively work with global supply chain partners to promote and implement industry best practices.

About PSCI (Pharmaceutical Supply Chain Initiative)
PSCI (Pharmaceutical Supply Chain Initiative) is a non-profit organization initiated by leading global pharmaceutical and healthcare companies. It aims to drive continuous improvement in safety, environment, business ethics, and labor rights within the supply chain through unified supplier standards and collaborative improvement mechanisms.